Pharmacokinetics and safety of bendamustine in the BEABOVP regimen for the treatment of pediatric patients with Hodgkin lymphoma

ConclusionsA single-day dose of 180  mg/m2 of bendamustine every 28  days was safe and well tolerated in pediatric patients. While age accounted for 23% of inter-individual variability observed in bendamustine clearance, the differences did not affect the safety and tolerability of bendamustine in our patient population.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research